Site-Specific Antibody-Drug Conjugates with Peptide Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates face limitations in delivering sufficient drug concentrations to target sites due to impaired binding and rapid in vivo clearance, largely because of non-specific conjugation methods that result in heterogeneous mixtures and unpredictable reaction conditions.
Innovation Solution
Development of site-specific antibody-drug conjugates using a peptide-containing scaffold with a divalent linker moiety and a therapeutic agent, allowing for controlled drug load and strong binding to target antigens, thereby enhancing the delivery of cytotoxic agents to specific cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If covalent conjugation of drug moieties to antibody through lysine or cysteine residues is used, then drug loading capacity is improved, but binding affinity to target antigen deteriorates and in vivo clearance increases
Solution Approach 1:
The patent introduces site-specific conjugation at defined locations on the antibody (e.g., N-terminal, C-terminal, or specific amino acid residues) rather than random conjugation at multiple lysine or cysteine residues. This localizes the drug attachment to specific sites that do not interfere with the antigen-binding region, thereby maintaining binding affinity while achieving controlled drug loading capacity.
Solution Approach 2:
The patent employs engineered antibody variants with pre-introduced modification sites (such as unnatural amino acids or specific glycosylation sites) that are designed beforehand to accommodate drug conjugation. This preliminary structural preparation ensures that subsequent drug attachment occurs at predetermined locations that preserve antigen-binding functionality while enabling controlled drug loading.
2Quantity of substance
If covalent conjugation of drug moieties to antibody is used, then drug loading capacity is improved, but manufacturing precision deteriorates due to heterogeneous mixtures
Solution Approach 1:
By restricting conjugation to a single or limited number of specific sites on the antibody (rather than multiple random sites), the patent produces a more homogeneous conjugate population with defined drug-to-antibody ratios. This site-specific approach eliminates the heterogeneous mixture problem associated with random lysine or cysteine conjugation, thereby improving manufacturing precision while maintaining adequate drug loading capacity.
Solution Approach 2:
The patent changes the conjugation parameters by using site-specific reactive groups (such as N-terminal alpha-amines, specific side chains, or engineered unnatural amino acids) that allow controlled attachment of a precise number of drug moieties. This parameter control ensures consistent drug-to-antibody ratios across the conjugate population, improving manufacturing precision and batch-to-batch reproducibility.
3Ease of operation
If conventional antibody-drug conjugates are used, then simplicity of administration is maintained, but therapeutic efficacy deteriorates due to rapid in vivo clearance
Solution Approach 1:
The patent creates composite antibody-drug conjugate structures with optimized physicochemical properties, including controlled drug-to-antibody ratios and site-specific positioning, that enhance plasma stability and reduce renal clearance. The engineered conjugate architecture combines the long circulation half-life of intact antibodies with the targeted delivery capability, maintaining simplicity of administration while significantly improving in vivo persistence and therapeutic efficacy.
Data Source
AI summary
The present disclosure relates generally to antibody-drug conjugates comprising peptide-containing linkers and to methods of using these conjugates as therapeutics and/or diagnostics. Also disclosed herein are peptide-containing scaffolds useful to conjugate with a targeting moiety (e.g., an antibody), a drug, or both to produce the antibody-drug conjugates.